Mahmoud Einieh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahmoud Einieh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abhijeet Kumar
Netaji Subhas Medical College and Hospital (NSMCH), Netaji Subhas Medical College and Hospital, Bihta, Patna, India
1 shared publication - Akash Rawat
Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India
1 shared publication - Anuja Anil Mandavkar
Vilasrao Deshmukh Government Medical College Latur Maharashtra India
1 shared publication - Ayush Dwivedi
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
1 shared publication - Iuri Ferreira Felix
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
1 shared publication - Jose Matias Zaldumbide Diaz
Universidad San Francisco de Quito, Quito, Ecuador
1 shared publication
Latest Publications
- Open Access
- 4 May 2026
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 27 (5) , 1980-1989
A meta-analysis of the hemodynamic and echocardiographic changes following arteriovenous fistula ligation in chronic kidney disease patients
Arteriovenous fistulas (AVFs) are the preferred method for establishing long-term vascular access in patients undergoing hemodialysis; however, high-flow AVFs may increase cardiovascular strain after kidney transplantation, often necessitating fistula closure. Currently, no established guideline exists for managing high-flow fistulas in post-transplant patients with stable kidney function, and available studies report heterogeneous results with small sample sizes and different methodologies. We performed a systematic search of PubMed, Cochrane, and Embase up to December 2024 for observational studies and randomized controlled trials comparing AVF ligation versus maintenance in patients with end-stage kidney disease. The meta-analysis was conducted using Cochrane’s RevMan software using mean difference (MD) and 95% confidence interval. Twelve studies including 844 patients were analyzed, of whom 409 (48%) underwent AVF ligation, with follow-up ranging from 3 to 62.5 months. AVF ligation was associated with a significant reduction in left ventricular mass index (MD −10.92 g/m 2 ; 95% confidence interval −17.84 to −3.99; p = 0.007) and cardiac index (MD −0.56 L/min/m 2 ; 95% confidence interval −1.05 to −0.07; p = 0.03), indicating attenuation of the hyperdynamic circulatory state related to a persistent AVF. No significant differences were observed in left ventricular ejection fraction or blood pressure parameters. Serum creatinine levels were modestly reduced following AVF ligation (MD −0.12 mg/dL; 95% confidence interval −0.22 to −0.03; p = 0.02), while estimated glomerular filtration rate remained unchanged. Overall, AVF ligation was associated with favorable cardiac remodeling reflected by reductions in left ventricular mass and cardiac output, with supportive changes in secondary echocardiographic parameters and no apparent deterioration in renal function.
- 4 May 2026
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 27 (5) , 1980-1989
Open AccessA meta-analysis of the hemodynamic and echocardiographic changes following arteriovenous fistula ligation in chronic kidney disease patients
Arteriovenous fistulas (AVFs) are the preferred method for establishing long-term vascular access in patients undergoing hemodialysis; however, high-flow AVFs may increase cardiovascular strain after kidney transplantation, often necessitating fistula closure. Currently, no established guideline exists for managing high-flow fistulas in post-transplant patients with stable kidney function, and available studies report heterogeneous results with small sample sizes and different methodologies. We performed a systematic search of PubMed, Cochrane, and Embase up to December 2024 for observational studies and randomized controlled trials comparing AVF ligation versus maintenance in patients with end-stage kidney disease. The meta-analysis was conducted using Cochrane’s RevMan software using mean difference (MD) and 95% confidence interval. Twelve studies including 844 patients were analyzed, of whom 409 (48%) underwent AVF ligation, with follow-up ranging from 3 to 62.5 months. AVF ligation was associated with a significant reduction in left ventricular mass index (MD −10.92 g/m 2 ; 95% confidence interval −17.84 to −3.99; p = 0.007) and cardiac index (MD −0.56 L/min/m 2 ; 95% confidence interval −1.05 to −0.07; p = 0.03), indicating attenuation of the hyperdynamic circulatory state related to a persistent AVF. No significant differences were observed in left ventricular ejection fraction or blood pressure parameters. Serum creatinine levels were modestly reduced following AVF ligation (MD −0.12 mg/dL; 95% confidence interval −0.22 to −0.03; p = 0.02), while estimated glomerular filtration rate remained unchanged. Overall, AVF ligation was associated with favorable cardiac remodeling reflected by reductions in left ventricular mass and cardiac output, with supportive changes in secondary echocardiographic parameters and no apparent deterioration in renal function.
- Open Access
- 17 December 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (1) , e70149
Circular RNAs as Biomarkers and Therapeutic Targets in Diabetic Cardiovascular Complications
Background: The global prevalence of diabetes mellitus (DM) is rising rapidly and is projected to reach unprecedented levels by 2035 and 2050, with a disproportionate burden among elderly populations and in low‐ and middle‐income countries. Diabetes‐related cardiovascular complications remain a leading cause of morbidity and mortality despite advances in glycaemic control and pharmacotherapy. There is an urgent need for novel molecular biomarkers and therapeutic targets to improve early detection, risk stratification, and personalised management. Methods: A comprehensive narrative review of the current literature was conducted to summarise emerging evidence on the biological roles of circular RNAs (circRNAs) in diabetes and its cardiovascular complications. Published experimental, translational, and clinical studies investigating circRNA expression, mechanisms of action, and therapeutic potential were critically analysed. Results: CircRNAs have emerged as key regulators in the pathophysiology of diabetes‐associated cardiovascular disorders, including diabetic cardiomyopathy, endothelial dysfunction, and vascular inflammation, as well as related microvascular complications. Mechanistically, circRNAs act through diverse pathways such as microRNA sponging, modulation of gene transcription, interaction with RNA‐binding proteins, and regulation of cellular processes including apoptosis, fibrosis, oxidative stress, and inflammation. Their covalently closed structure confers exceptional stability, while their tissue‐ and disease‐specific expression profiles support their utility as sensitive biomarkers for early diagnosis, prognosis, and therapeutic monitoring. Advances in synthetic circRNA design further highlight their promise as novel therapeutic agents, although challenges related to delivery efficiency, specificity, and off‐target effects remain. Conclusions: CircRNAs represent a promising class of biomarkers and therapeutic targets in diabetes‐related cardiovascular complications. Their stability, specificity, and functional versatility position them as attractive tools for precision medicine approaches in diabetes care. Further mechanistic studies and well‐designed clinical investigations are essential to translate circRNA‐based diagnostics and therapeutics into clinical practice.
- 17 December 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (1) , e70149
Open AccessCircular RNAs as Biomarkers and Therapeutic Targets in Diabetic Cardiovascular Complications
Background: The global prevalence of diabetes mellitus (DM) is rising rapidly and is projected to reach unprecedented levels by 2035 and 2050, with a disproportionate burden among elderly populations and in low‐ and middle‐income countries. Diabetes‐related cardiovascular complications remain a leading cause of morbidity and mortality despite advances in glycaemic control and pharmacotherapy. There is an urgent need for novel molecular biomarkers and therapeutic targets to improve early detection, risk stratification, and personalised management. Methods: A comprehensive narrative review of the current literature was conducted to summarise emerging evidence on the biological roles of circular RNAs (circRNAs) in diabetes and its cardiovascular complications. Published experimental, translational, and clinical studies investigating circRNA expression, mechanisms of action, and therapeutic potential were critically analysed. Results: CircRNAs have emerged as key regulators in the pathophysiology of diabetes‐associated cardiovascular disorders, including diabetic cardiomyopathy, endothelial dysfunction, and vascular inflammation, as well as related microvascular complications. Mechanistically, circRNAs act through diverse pathways such as microRNA sponging, modulation of gene transcription, interaction with RNA‐binding proteins, and regulation of cellular processes including apoptosis, fibrosis, oxidative stress, and inflammation. Their covalently closed structure confers exceptional stability, while their tissue‐ and disease‐specific expression profiles support their utility as sensitive biomarkers for early diagnosis, prognosis, and therapeutic monitoring. Advances in synthetic circRNA design further highlight their promise as novel therapeutic agents, although challenges related to delivery efficiency, specificity, and off‐target effects remain. Conclusions: CircRNAs represent a promising class of biomarkers and therapeutic targets in diabetes‐related cardiovascular complications. Their stability, specificity, and functional versatility position them as attractive tools for precision medicine approaches in diabetes care. Further mechanistic studies and well‐designed clinical investigations are essential to translate circRNA‐based diagnostics and therapeutics into clinical practice.